Johnson & Johnson's RYBREVANT® (amivantamab-vmjw) plus chemotherapy delivers longest reported median overall survival in EGFR exon 20 insertion mutation-positive lung cancer
RYBREVANT plus chemotherapy shows longest reported median overall survival in EGFR exon 20 lung cancer.
What changed
RYBREVANT plus chemotherapy shows longest reported median overall survival in EGFR exon 20 lung cancer.
Why it matters
RYBREVANT plus chemotherapy shows longest reported median overall survival in EGFR exon 20 lung cancer. — impact context not separately stored; see What changed.
← Dashboard
Sep 14, 2026 02:58 AM ET